Ming Lu

About

Seasoned Clinical Pharmacology leader with 20 years of experience in early development, clinical pharmacology, and translational medicine in pharmaceutical/biotech. Experienced in the development of small molecules and biologics (antibody, peptides, and vaccines) in CNS, Immunology, Oncology, Cardiovascular/Metabolic disease areas. Successful BLA and NDA submissions with health authorities including US, Canada, EU, and Asia Pacific region.

Experience

• Vice President Clinical Pharmacology at Avenzo Therapeutics
  Jan 2024 - Present · 2 yrs 6 mos

• Vice President Clinical Pharmacology at Bristol Myers Squibb
  Aug 2022 - Aug 2023 · 1 yr 1 mo

• Vice President, Clinical Pharmacolgy at Turning Point Therapeutics
  Mar 2022 - Aug 2023 · 1 yr 6 mos

  Managed Clinical Pharmacology and Bioanalytical functions and provided clinical pharmacology development strategy for oncology assets. Led the successful US NDA submissions and approval of AUGTYRO™ (repotrectinib).

• Vice President Clinical Pharmacology at Ascentage Pharma
  Sep 2018 - Mar 2022 · 3 yrs 7 mos

  Developed clinical pharmacology strategy for the oncology and hepatitis B portfolios including HQP1351 (a third generation TKI), APG-2575 (a BCL-2 inhibitor), APG-115 (a MDM2 antagonist), APG-1252 (a BCL-2/BCL-xL dual inhibitor), APG-1387 (an IAP inhibitor), and APG-2449 (a FAK/ALK/ROS1 inhibitor) Successfully submitted the first company NDA for Olverembatinib (HQP1351) and gained approval in China

• The Janssen Pharmaceutical Companies of Johnson & Johnson (Spring House, PA)
  • Scientific Director, Global Clinical Pharmacology
    Apr 2007 - Aug 2018 · 11 yrs 5 mos

  • Director, Biologics Clinical Pharmacology
    2007 - 2016 · 9 yrs